secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001999480-24-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q1 net loss $13.4M; cash $205.9M; pipeline on track for multiple readouts
--------------------------------------------------------------------------------

- Net loss $13.4M vs $7.3M YoY; R&D expenses $10.0M, G&A $4.4M, both up on clinical study costs and public company expenses.
- Cash and equivalents $205.9M as of March 31, 2024; expects to fund operations into 2027.
- Initiated Phase 2 study of ALTO-203 in MDD with anhedonia; reported positive Phase 1 data for transdermal ALTO-101 with improved tolerability.
- Phase 2b studies of ALTO-100 and ALTO-300 in MDD enrolling; topline data for ALTO-100 expected 2H 2024, ALTO-300 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/0001999480-24-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948024000020/alto-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001999480-24-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer